Call to Action: Combat illegal xylazine while protecting veterinary access
April 7, 2023 —
Xylazine is an important animal sedative used to facilitate the safe handling and treatment of many species. Recently, illicit xylazine is increasingly showing up in street drugs as traffickers have begun mixing xylazine with fentanyl and other narcotics.
Collaborative efforts among congressional offices, the AVMA, stakeholders, and federal agencies to address the complexities of the xylazine issue led to the introduction of the Combating Illicit Xylazine Act (H.R. 1839/S. 993) - an AVMA-supported, bipartisan bill that would provide harsher penalties for trafficking illicit xylazine while maintaining current veterinary access to this important animal sedative.
Please join the veterinary community and urge your members of Congress to support the Combating Illicit Xylazine Act through the AVMA's Congressional Advocacy Network.
LINK: https://avmacan.avma.org/campaign/46288/
[Source: AVMA 6 April 2023]
- Next story: Zoetis Foundation Announces First Round of 2023 Grants to Advance Farmer and Veterinarian Education, Livelihoods and Well-being
- Next in category: AVMA Pledges to Defend Against Expanding Scope of Practice
- Previous in category: Over-the-Counter Antibiotics: What You Need to Know Before June 11
- Previous story: Webinar April 26 - Mycoplasma hyopneumoniae (Mhp): Impact, management approaches and new diagnostic technology